OMNISEQ, INC.
Genomic sequencing and molecular testing platform for oncology
- Sector
- Medtech
- Headquarters
- BUFFALO, NY
- Founded
- 2015
- Latest Form D
- $1.6M, Jun 2019
- Total capital
- $18.9M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $18.9M
- 3 Form D · last Jun 2019
- 88 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 3
- 17 pending · first 2022
- Rank in peer group#39 of 160
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 3rd filing$1.6M
- Private capital raisedForm D · SEC · 2nd filing$7.3M
- Private capital raisedForm D · SEC · 1st filing$10M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 160 peers
Line = medianMedtech · Instrument
- Granted patents#39 · top 24%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- CARL MORRISONResearcherExecutive Officer, DirectorLinked by 3 patents
- CANDACE JOHNSONDirectorNamed in SEC Form D filings
- KENNETH A. MANNINGDirectorNamed in SEC Form D filings
- Marcia Buford EisenbergDirectorNamed in SEC Form D filings
- Margot SchoenbornExecutive OfficerNamed in SEC Form D filings
- MARK GARDNERExecutive OfficerNamed in SEC Form D filings
Show all 10 people
- Mark GarnerExecutive Officer, DirectorNamed in SEC Form D filings
- Paul Buford BillingsDirectorNamed in SEC Form D filings
- R. BUFORD SEARSDirectorNamed in SEC Form D filings
- Steven Buford AndersonDirectorNamed in SEC Form D filings
What it has protected
USPTO · 3 granted of 20- PendingKnowledge Informatics Auto Reviewer For Quality Control Of ReportingUSPTOApplication 19208265
- GrantedMethods And Systems For Determining Personalized TherapiesUSPTOUS 12,475,974
- PendingConsensus-based Classification Technique To Determine Genetically Inferred Ancestry From Comprehensive Genomic Profiling Of Tumor DnaUSPTOApplication 19070502
Show all 20 patent records
- Knowledge Informatics Auto Reviewer For Quality Control Of ReportingNov 20, 2025 · Application 19208265Pending
- Methods And Systems For Determining Personalized TherapiesNov 18, 2025 · US 12,475,974Granted
- Consensus-based Classification Technique To Determine Genetically Inferred Ancestry From Comprehensive Genomic Profiling Of Tumor DnaSep 4, 2025 · Application 19070502Pending
- Methods And Systems For Analyzing And Utilizing Cancer Testis Antigen BurdenFeb 6, 2025 · Application 18883641Pending
- Methods and Systems for Analyzing and Utilizing Cancer Testis Antigen BurdenMay 25, 2023 · Application 18055292Pending
- Methods And Systems For Determining Personalized TherapiesNov 29, 2022 · US 11,515,008Granted
- Methods And Systems For Assessing Proliferative Potential And Resistance To Immune Checkpoint BlockadeAug 30, 2022 · US 11,427,873Granted
- Methods And Systems For Characterizing Tumor Response To Immunotherapy Using An Immunogenic ProfileMay 5, 2022 · Application 17452873Pending
- Methods And Systems For Analyzing And Utilizing Cancer Testis Antigen BurdenApplication PCTUS2022049867Pending
- Methods And Systems For Analyzing Cancer Testis Antigen BurdenApplication 63263913Pending
- Methods And Systems For Assessing Proliferative Potential And Resistance To Immune Checkpoint BlockadeApplication PCTUS2019045962Pending
- Cancer Testis Antigen Burden (ctab) As A Biomarker Of Tumor-associated AntigensApplication PCTUS2025046237Pending
- Methods And Systems For Determining Personalized TherapiesApplication PCTUS2017055545Pending
- Ai-based Multi-omics Data Processing For Detection Of Genomic InstabilityApplication PCTUS2025031499Pending
- Knowledge Informatics Auto Reviewer For Quality Control Of ReportingApplication PCTUS2025029368Pending
- Consensus-based Classification Technique To Determine Genetically Inferred Ancestry From Comprehensive Genomic Profiling Of Tumor DnaApplication PCTUS2025018426Pending
- Ai-based Multi-omics Data Processing For Detection Of Genomic InstabilityApplication 63765274Pending
- Machine Learning Algorithm Based on Multi-Omics Biomarkers for the Detection of Tumor Microsatellite InabilityApplication 63652983Pending
- Knowledge Information AutoreviewerApplication 63647572Pending
- Consensus-based Classification Technique To Determine Genetically Inffered Ancestry From Comprehensive Genomic Profiling Of Tumor DnaApplication 63561247Pending
Related companies, and why
- SkinIO, Inc.Similar federal contract value in Medtech · null in contracts
- Eleven P15 Inc.Similar federal contract value in Medtech · null in contracts
- VuEssence, Inc.Similar federal contract value in Medtech · null in contracts
- IC Surgical, Inc.Similar federal contract value in Medtech · null in contracts
- StimAire, Inc.Similar federal contract value in Medtech · null in contracts
- MEDICREASimilar federal contract value in Medtech · null in contracts
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .